J&J(US:JNJ) CNBC Television·2025-09-27 00:43Financial Performance & Investment - Johnson & Johnson's stock has increased by over 24% year-to-date [1] - The company is investing $55 billion in the US over the next four years, a 25% increase compared to the previous four years [3] - Q2 performance was stellar, exceeding analyst expectations and substantially increasing guidance, with expectations for continued growth in the coming years [21] - The stock is considered inexpensive with a 3% yield [20][21] Innovation & Pipeline - Advances in biology and chemistry, amplified by artificial intelligence, are expected to lead to cures for previously incurable diseases [6][7] - Cell therapy carvicti shows promising results in treating multiple myeloma, with patients disease-free 5 years after a single administration [8] - FDA approved Inlexo, a groundbreaking therapy for bladder cancer, allowing patients to keep their bladder [10][11] - Acquisition Abomemed is performing well, with data showing patients living 600 days longer after a heart attack with cardiogenic shock [12][13] US Operations & Manufacturing - Johnson & Johnson is breaking ground in North Carolina for a major biologics plant [5] - The company aims to manufacture essentially all advanced medicines in the US [5] - The company has been in New Brunswick, New Jersey for 140 years [4] Legal & Ethical Considerations - The company is fighting claims related to talc and has not paid a single penny since returning to the tort system [17][18] - Johnson & Johnson has won 16 out of 17 cases in ovarian cancer over the last 11 years [18]